<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">Pseudotumor cerebri</z:e> is an <z:e sem="disease" ids="C0277553" disease_type="Disease or Syndrome" abbrv="">idiopathic disorder</z:e> characterized by <z:hpo ids='HP_0001085'>papilledema</z:hpo> and <z:e sem="disease" ids="C0151740" disease_type="Disease or Syndrome" abbrv="">elevated intracranial pressure</z:e> without a mass lesion </plain></SENT>
<SENT sid="1" pm="."><plain>Most patients are female and young and are either overweight or have a history of recent <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Other <z:mp ids='MP_0002054'>disease states</z:mp>, such as <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, and drugs, such as <z:chebi fb="9" ids="27902">tetracycline</z:chebi>, have also been associated with the development of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanism is unclear, but is likely related to decreased cerebrospinal fluid (CSF) resorption </plain></SENT>
<SENT sid="4" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> patients have <z:hpo ids='HP_0002315'>headache</z:hpo>, but the greatest morbidity of the disorder is <z:hpo ids='HP_0000572'>visual loss</z:hpo> related to optic disc swelling </plain></SENT>
<SENT sid="5" pm="."><plain>Common radiographic findings in <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> include an empty sella, dilation of the optic nerve sheaths and elevation of the optic disc </plain></SENT>
<SENT sid="6" pm="."><plain>The CSF, aside from elevated opening pressure, is <z:mpath ids='MPATH_458'>normal</z:mpath> without evidence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment of patients with no or mild to moderate <z:hpo ids='HP_0000572'>visual loss</z:hpo> is primarily medical, with <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> as the first-line agent </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="27690">Acetazolamide</z:chebi> decreases CSF production </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="47426">Furosemide</z:chebi> and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> are secondary choices </plain></SENT>
<SENT sid="10" pm="."><plain>Optic nerve surgery is reserved for patients with severe <z:hpo ids='HP_0000572'>visual loss</z:hpo> or progression in visual deficits despite medical management </plain></SENT>
</text></document>